Related Experiment Video
Updated: Jun 2, 2026
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel
Kenji Zennami1, Kazuhiro Yoshikawa, Eisaku Kondo
1Department of Urology, Aichi Medical University School of Medicine, Nagakute, 480-1195 Aichi, Japan.
Abstract:
Molecular targeting agents have become formidable anticancer weapons showing much promise against refractory tumors and functional peptides and are among the more desirable of these nanobio-tools. Intracellular delivery of multiple functional peptides forms the basis for a potent, non-invasive mode of delivery, providing distinctive therapeutic advantages. We examine the growth suppression efficiency of human renal cell carcinoma (RCC) by single-peptide targeting. We simultaneously introduced p16INK4a tumor suppressor peptides by Wr-T-mediated peptide delivery. Wr-T-mediated transport of p16INK4a functional peptide into 10 RCC lines, lacking expression of the p16INK4a molecule, reversed the specific loss of p16 function, thereby drastically inhibiting tumor growth in all but 3 lines by >95% within the first 96 h. In vivo analysis using SK-RC-7 RCC xenografts in nude mice demonstrated tumor growth inhibition by the p16INK4a peptide alone, however, inoculation of Wr-T and the p16INK4a functional peptide mixture, via the heart resulted in complete tumor regression. Thus, restoration of tumor suppressor function with Wr-T peptide delivery represents a powerful approach, with mechanistic implications for the development of efficacious molecular targeting therapeutics against intractable RCC.
Insights
Restoring tumor suppressor function with Wr-T peptide delivery significantly inhibited renal cell carcinoma (RCC) growth. This molecular targeting approach led to over 95% tumor reduction in most lines and complete regression in vivo.
Area of Science:
- Oncology
- Molecular Biology
- Nanotechnology
Background:
- Refractory tumors pose a significant challenge in cancer therapy.
- Functional peptides are promising nanobio-tools for targeted drug delivery.
- Intracellular delivery of peptides offers potent, non-invasive therapeutic advantages.
Purpose of the Study:
- To evaluate the efficacy of single-peptide targeting for inhibiting human renal cell carcinoma (RCC) growth.
- To investigate the use of Wr-T-mediated delivery for introducing p16INK4a tumor suppressor peptides into RCC cells.
Main Methods:
- Wr-T-mediated peptide delivery was used to introduce p16INK4a functional peptide into 10 human RCC lines.
- In vitro experiments assessed tumor growth inhibition.
- In vivo studies utilized SK-RC-7 RCC xenografts in nude mice to evaluate tumor regression.
Main Results:
- Wr-T-mediated delivery of p16INK4a peptide reversed p16 function loss in RCC lines, inhibiting tumor growth by over 95% within 96 hours in most cases.
- In vivo, the p16INK4a peptide alone showed tumor growth inhibition.
- Combined administration of Wr-T and p16INK4a peptide via the heart resulted in complete tumor regression in xenografts.
Conclusions:
- Restoration of tumor suppressor function via Wr-T peptide delivery is a powerful strategy against intractable RCC.
- This approach has significant mechanistic implications for developing targeted molecular therapies.
- Wr-T-mediated delivery offers a promising route for effective cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...